CTAGE13P

Across TCGA pan-cancer cohorts, CTAGE13P RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated CTAGE13P data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher CTAGE13P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CTAGE13P expression acts as an unfavorable survival marker, although some lineages such as BLCA and ESCA show a favorable association.

CHOL, STAD, and BRCA are the cancer types where CTAGE13P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	III,IV	0.024	0.772	.008	54	view →
STAD	DFS	Median	II,III,IV	0.406	0.631	<.001	49	view →
BRCA	OS	Tertile	IV	0.383	0.802	.016	36	view →
BLCA	DFS	Tertile	IV	1.000	0.286	.009	36	view →
ACC	DFS	Tertile	IV	0.045	0.339	.009	30	view →
UVM	DFS	Tertile	All	0.079	0.746	<.001	27	view →
ESCA	OS	Quartile	II,III,IV	0.699	0.407	.003	25	view →
LUSC	OS	Tertile	All	0.749	0.644	.008	15	view →
KIRC	DFS	Tertile	IV	0.512	0.200	.026	12	view →
UCEC	DFS	Quartile	All	0.948	0.884	.013	12	view →
LUAD	OS	Tertile	All	0.693	0.822	.011	11	view →
SKCM	OS	Quartile	All	0.854	0.761	.011	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

CTAGE13P–CHOL (OS)

Open the CHOL breakdown →